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these, 4,856 patients had received dronedarone according to the Swedish Drug Register, and 170,139 patients who
had not were used as a control population. Mean follow-up was 1.6 years, with a minimal follow-up of 6 months.Results Patients prescribed dronedarone were younger (age 65.5 years vs. 75.7 years, p < 0.0001) and healthier than
control patients. The annual mortality rate among patients who received dronedarone was 1.3% compared with
14.0% in the control population. There were no sudden cardiac deaths and no deaths related to liver failure among
patients who received treatment with dronedarone. After propensity score matching and adjustment for cofactors,
patients who received dronedarone had lower mortality than other AF patients (hazard ratio [HR]: 0.41; 95%
conﬁdence interval [CI]: 0.33 to 0.51). Dronedarone patients with heart failure had lower mortality than other heart
failure patients (HR: 0.40; 95% CI: 0.30 to 0.53). They also had lower mortality than expected from the general
population (standardized mortality ratio: 0.67; 95% CI: 0.55 to 0.78), which indicates the selection of low-risk
patients. The risk of liver disease was not increased (HR: 0.57; 95% CI: 0.34 to 0.92).Conclusions Dronedarone, as prescribed to AF patients in Sweden, has not exposed patients to increased risks of death or liver
disease. (J Am Coll Cardiol 2014;63:2376–84) ª 2014 by the American College of Cardiology FoundationSee page 2385Dronedarone is an antiarrhythmic drug for treatment of
atrial ﬁbrillation (AF). It was synthesized in search of an
antiarrhythmic substance with fewer side effects than
amiodarone, of which it is a derivative, and with less risk
of proarrhythmia and sudden death than sotalol and
Vaughan-Williams class I drugs (1–3). The safety and ef-
ﬁcacy of dronedarone were tested against placebo in several
trials in patients with nonpermanent and permanent AF,
including DAFNE (Dronedarone Atrial Fibrillation
Study After Electrical Cardioversion) (4), the EURIDIS/
ADONIS (EURopean Trial In Atrial Fibrillation (AF) or
Flutter [AFL] Patients Receiving Dronedarone for
the maintenance of Sinus Rhythm and the American-
Australian-African Trial With Dronedarone in Patients
With Atrial Fibrillation or Atrial Flutter for the Mainte-
nance of Sinus Rhythm) (5), ERATO trial (Efﬁcacypartment of Cardiology at Danderyd Hospital,
as funded by the Swedish Heart and Lung
nty Council. Dr. Friberg has participated in
for Bayer HealthCare, Boehringer Ingelheim,
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013; revised manuscript received February 2,and safety of dRonedArone for The cOntrol of ventricular
rate during atrial ﬁbrillation) (6), and ATHENA (A Trial
With Dronedarone to Prevent Hospitalization or Death in
Patients With Atrial Fibrillation) (7), as well as in patients
with severe heart failure, the ANDROMEDA (EuropeanTrial of Dronedarone in Moderate to Severe Congestive
Heart Failure) (8). A comparative study against amiodarone
was also conducted (DIONSYSOS [Efﬁcacy & Safety of
Dronedarone Versus Amiodarone for the Maintenance
of Sinus Rhythm in Patients With Atrial Fibrillation]) (9).
One of the studies was stopped early because of increased
mortality among patients with heart failure (8). Accord-
ingly, the approvals by the U.S. Food and Drug Admin-
istration (FDA) and by the European Medicines Agency
(EMA) in 2009 stated that dronedarone must not be used
for patients with symptoms of heart failure at rest or with
minimal exertion (corresponding to patients with New
York Heart Association functional class IV and unstable
class III heart failure).
In January 2011, after almost 150,000 patients in the
United States had been prescribed dronedarone, reports
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2377about possible liver toxicity led to the issuance of a warn-
ing from the FDA. The EMA prescribed continuous sur-
veillance with monthly liver function tests during the ﬁrst
6 months. Less than a year later, the PALLAS trial (Per-
manent Atrial ﬁbriLLAtion Outcome Study Using Dro-
nedarone on Top of Standard Therapy) was stopped early
because of an unexpected increase in mortality among pa-
tients with permanent AF who were treated with drone-
darone (10). This prompted the FDA and EMA to issue
another warning: Dronedarone should not be prescribed
to patients with permanent AF.
Antiarrhythmic drugs are problematic, because they may
cause dangerous ventricular arrhythmias, and side effects are
frequent. Given that 2 dronedarone trials have been stopped
for safety reasons, it is essential to ensure that dronedarone
will have an acceptable adverse effect proﬁle when put into
daily clinical use.
Aim
The aim of this study was to determine the “real-world”
safety of dronedarone, speciﬁcally with regard to all-cause
mortality, mortality attributable to liver disease and heart
failure, and incidence of liver disease among patients treated
with dronedarone.
Methods
Inclusion period. The ﬁrst purchase of dronedarone in
Sweden was made on May 24, 2010, which therefore serves
as the start date of the inclusion period. The inclusion period
lasted until December 31, 2012.
Follow-up. Patients were followed up for a minimum of
6 months with regard to all-cause mortality (until July 1,
2013). For cause-speciﬁc mortality and for incidence of
liver-related morbidity, follow-up ended on December 31,
2012, because of delayed reporting from the registers.
Study population. All subjects who received dronedar-
one at least once in a pharmacy in Sweden during the study
period constituted the study population. The control pop-
ulation consisted of all subjects in Sweden with a hospital
diagnosis of AF who had not been prescribed dronedarone.
Study patients and control patients were identiﬁed from the
Swedish Patient Register and the Swedish Prescribed Drug
Register. The inclusion period was May 24, 2010, through
December 31, 2012. All patients given dronedarone also
had a diagnosis of AF in the Patient Register.
For patients given dronedarone, the index date was
deﬁned by the ﬁrst purchase of dronedarone, and time at
risk was counted from that date. For control patients, the
index date was deﬁned by the ﬁrst occurrence of a diagnosis
of AF in the Patient Register after May 24, 2010. For the
control group, we applied a blanking period of 14 days,
with the result that patients who died within 14 days of the
index date were excluded. Furthermore, this minimized
double counting of early reappearances of diagnoses, which
were often not caused by new events but were repetitions ofdiagnoses that caused the initial
hospital stay. New diagnoses
given during the ﬁrst 14 days
after the index date were there-
fore counted as being part of the
baseline comorbidity, and time at
risk for control patients was
calculated from the index date
plus 14 days. Censoring was
made at the date of the event or
on June 30, 2013.
Data sources. All Swedish res-
idents have a unique 10-digit civic registration number, of
which the ﬁrst 6 digits indicate the birth date and the ninth
indicates the sex of subject. These numbers are used in all
contacts with the healthcare system throughout the country,
including when prescribed drugs are purchased in pharma-
cies. By merging information from different registers, it is
possible to investigate associations between comorbidity,
medication, and outcome on a national scale. To protect
personal integrity, linking of registers is strictly regulated by
Swedish law. When ﬁles have been combined, personal
identities are replaced by anonymized numbers before the
researcher obtains access to them.
The Patient Register. The Patient Register contains
detailed information about hospital stays and visits to
hospital-afﬁliated open clinics, for instance, dates of admis-
sion and discharge, principal and secondary diagnoses, and
procedural and surgical codes for each hospital period. For
the description of previous and current diseases, the search
was limited to diagnoses given from 1997. Both principal and
secondary diagnoses were used for the description of previous
and current diseases and for detection of liver problems
during follow-up. The mean number of diagnoses in the
register increased from 1.7 in 1997 to 4.9 in 2012. The use of
secondary diagnoses is less well established in conjunction
with open clinic visits; the mean number of diagnoses on
each contact was 0.9 in 2001 and 1.6 in 2012.
The Patient Register is validated annually by the Board
of Health and Welfare in Sweden. More than 99% of all
hospital discharges are technically correct (11). Generally,
the validity of diagnoses in the register is good but varies
among diagnoses. For example, a diagnosis of AF at hospital
discharge is correct in 97% of cases (12); for most other
diagnoses, the positive predictive values are in the range of
85% to 95% (13).
The Prescribed Drug Register. The Prescribed Drug
Register stores details about every prescription that has been
handled in every pharmacy in Sweden since July 1, 2005.
Each pharmacy is required to participate by law. The register
is run by a governmental agency, the Swedish Board of
Health and Welfare, and is almost 100% complete because
the information is transferred electronically when a drug
is dispensed. It contains information about 42 variables for
each purchase, including the name of the drug, its strength,
quantity, dosing instruction, date of prescription, and date
Table 1
Clinical Characteristics of AF Patients With and
Without Dronedarone
Dronedarone
p Value
Yes
(n ¼ 4,856)
No
(n ¼ 170,139)
Age, yrs* 65.5  9.9 75.7  12.1 <0.0001
75 yrs 17.2 59.5 <0.0001
Sex* <0.0001
Men 58.8 55.6
Women 41.2 44.4
CHADS2 score 1.3  1.1 2.3  1.5 <0.0001
CHA2DS2-VASc score 2.5  1.6 3.8  1.9 <0.0001
HAS-BLED score 1.9  1.1 2.6  1.2 <0.0001
Heart failure* 16.7 32.5 <0.0001
Hypertension* 65.7 68.4 <0.0001
Diabetes mellitus* 11.3 19.5 <0.0001
Ischemic stroke 6.3 14.9 <0.0001
Thromboembolism (arterial)* 12.0 23.5 <0.0001
Myocardial infarction 11.3 19.0 <0.0001
Ischemic heart disease 19.3 27.6 <0.0001
Revascularization
(PCI or CABG)
9.4 12.0 <0.0001
Vascular disease
(as in CHA2DS2-VASc)
*
14.1 24.3 <0.0001
Peripheral arterial disease 4.0 8.0 <0.0001
Valvular AF* (mitral stenosis
or mechanical valve)
3.8 4.8 0.002
Other valvular disease* 8.9 11.4 <0.0001
Pacemaker or ICD* 9.2 9.4 0.73
Renal failure* 2.0 6.6 <0.0001
Liver disease* 0.8 1.4 0.001
Thyroid disease* 9.9 8.8 0.001
Chronic obstructive
pulmonary disease*
4.6 8.3 <0.0001
Venous thromboembolism* 3.4 5.3 <0.0001
Any bleeding* 12.6 21.5 <0.0001
Intracranial bleeding 0.8 2.1 0.0001
Gastrointestinal bleeding 4.3 7.0 <0.0001
Other bleeding 8.0 10.4 <0.0001
Transfusion 1.7 7.6 <0.0001
Anemia* 4.0 10.7 <0.0001
Coagulation or platelet defect* 2.1 2.6 0.046
Cancer within 3 yrs* 13.8 19.0 <0.0001
Alcohol index* 1.5 3.2 <0.0001
Dementia* 0.1 4.7 <0.0001
Values are mean  SD or %. *Factors used in multivariable analyses in Table 3.
AF ¼ atrial ﬁbrillation; CABG ¼ coronary artery bypass graft surgery; CHADS2 ¼ score on the
basis of history of congestive heart failure, hypertension, age 75 years, history of diabetes
mellitus, and previous stroke or transient ischemic attack symptoms; CHA2DS2-VASc ¼ score on
the basis of age, sex, and history of congestive heart failure, hypertension, diabetes mellitus,
stroke/transient ischemic attack/thromboembolism, and vascular disease; HAS-BLED ¼ score on
the basis of history of hypertension, renal disease, liver disease, stroke, prior major bleeding or
predisposition to bleeding, labile international normalized ratio, age >65 years, medication usage
predisposing to bleeding, and alcohol usage history; ICD ¼ implantable cardioverter-deﬁbrillator;
PCI ¼ percutaneous coronary intervention.
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2378of purchase. We considered drugs that had been dispensed
within 5 months before the index date and up to 1 month
after the index date as reﬂecting baseline treatment. Infor-
mation about drug purchases was available for the entire
study period up to July 1, 2013.
Deﬁnitions. Previous disease, comorbid conditions, and
endpoint events were deﬁned by coding according to the
International Classiﬁcation of Diseases-Tenth Revision.
The speciﬁc codes used are presented in Online Table 1.
Risk stratiﬁcation scores for AF-related stroke (CHADS2,
CHA2DS2-VASc) (14,15) and for bleeding (modiﬁed
HAS-BLED) (16) were calculated for each patient by use of
information from these registries (Online Appendix).
Statistical methods. Baseline characteristics are presented
descriptively, and differences were tested with Student t test
and chi-square test. Incidences were calculated as events per
100 years at risk (expressed as percents in the text) and
presented with Poisson rate conﬁdence intervals (CIs).
Survival is presented graphically by the Kaplan-Meier
method and was analyzed with univariate and multivariate
Cox regressions. In the multivariate models, we included
comorbidities and medications as speciﬁed in Table 1 and
Online Table 2.
We compared the observed number of deaths with the
expected mortality on the basis of sex- and age-speciﬁc
(1-year age groups) mortality in the general population by
calculating standardized mortality ratios (SMRs). CIs were
calculated with the assumption that the observed number
of deaths followed a Poisson distribution.
To minimize confounding by indication (i.e., that patients
selected for dronedarone treatment are different from pa-
tients not given dronedarone), propensity score analysis was
used. First, a binomial logistic regression was made with
factors entered that may have affected the decision to
commence dronedarone treatment. From this analysis, a
probability score was obtained that showed each patient’s
likelihood of being prescribed dronedarone. Second, patients
with and without treatment for dronedarone were matched
in a pairwise fashion according to their individual scores,
after which multivariate Cox regression analysis was per-
formed on a population thus made less heterogeneous.
The main analyses were performed with patients grouped
according to medication at baseline, in accordance with the
intention-to-treat principle. By deﬁnition, no patients in the
control group could cross over to dronedarone treatment, but
patients prescribed dronedarone could stop taking it during
follow-up. To account for that possibility, a ratio was
calculated by dividing the number of days the dispensed
quantity would last by the number of days at risk. In analyses
according to the on-treatment principle, patients with access
to less dronedarone than needed to cover 80% of the time
at risk were considered to have discontinued treatment.
Values of p < 0.05 were considered signiﬁcant. All analyses
were performed with SPSS 22.0 (IBM SPSS Statistics, IBM
Corporation, Somers, New York).Ethical approval. Approval for the study was obtai-
ned from the regional ethics committee in Stockholm
(EPN 2010/2032-31/3, EPN 2011/690-32, and EPN
2012/1914-32).
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2379Results
Baseline characteristics. Dronedarone was dispensed to
4,856 unique patients in Sweden between May 24, 2010,
and December 31, 2012. The control group consisted of
170,139 patients who had received a diagnosis of AF during
the same period but who had not received dronedarone.
Patients prescribed dronedarone were younger (65.5 years
vs. 75.7 years, p < 0.0001) and healthier than AF patients
not given dronedarone (Table 1), used oral anticoagulant
agents more often than other AF patients (73% vs. 49%,
p < 0.0001), and had tried more antiarrhythmic drugs
(Online Table 2). More than one-half of the dronedarone
patients had tried 1 or more class I or class III antiar-
rhythmic agents before they began taking dronedarone
(n ¼ 2,455 of 4,856).
Drug persistence. Among patients who received drone-
darone, the dispensed quantity was only sufﬁcient to cover
51% of the days at risk, which indicates that the discon-
tinuation rate was high, especially among patients who
began taking dronedarone in 2010, of whom 55% had
access to less dronedarone than would be needed to cover
80% of the time at risk. By 2012, that proportion had fallen
to 35%.
Mortality. During a median follow-up of 598 days (1.6
years), 128 patients in the dronedarone group died, which
represents an annualized mortality rate of 1.3% (95% CI:
1.1% to 1.6%) compared with 14.0% (95% CI: 13.9% toFigure 1
Unadjusted Mortality in Patients Exposed to
Dronedarone
Unadjusted mortality in 4,856 patients with atrial ﬁbrillation exposed to
dronedarone compared with 170,139 patients with atrial ﬁbrillation not exposed
to dronedarone. Cum ¼ cumulative.14.2%; p < 0.0001) in the control population (Fig. 1). After
propensity score matching, patients given dronedarone still
had a lower mortality rate than control patients (1.31% vs.
2.73%, p < 0.0001) (Fig. 2).
One-half of the dronedarone patients who died (66/128)
must have stopped taking dronedarone before they died,
because their supplies could not have lasted more than
25% of the time at risk. Among patients with supplies that
lasted for 80% of the follow-up period, the annualized
mortality rate was 0.43% (95% CI: 0.23% to 0.73%)
compared with 1.55% (95% CI: 1.28% to 1.86%) among
patients without sufﬁcient supplies (p < 0.0001).
Information about cause-speciﬁc mortality was available
until the end of 2012, during which time 95 dronedarone-
exposed patients died (Online Table 3). The most com-
mon cause of death in the dronedarone group, when both
principal and contributory causes were included, was cancer
(38%), followed by heart failure (24%) and acute myocardial
infarction (14%).
One dronedarone-exposed patient had sudden cardiac
death. That patient had made a single purchase of drone-
darone that was supposed to last 50 days and died 6 months
later after having switched to amiodarone. There were no
deaths with liver failure or liver disease listed as the principal
or contributory cause of death.
Adjustment for previous and current diseases and medi-
cation did not alter the apparent survival beneﬁt for
patients taking dronedarone (HR: 0.32; 95% CI: 0.27 toFigure 2
Unadjusted Mortality After Pairwise Matching
for Propensity to Receive Dronedarone
Patients with atrial ﬁbrillation exposed to dronedarone (n ¼ 4,856) compared
with patients with atrial ﬁbrillation not exposed to dronedarone (n ¼ 4,856).
Cum ¼ cumulative.
Table 2
Hazard Ratios for Death of Any Cause With
Dronedarone, With No Dronedarone as Reference
Adjustment
Intention to Treat
(At Least
1 Purchase)
On Treatment
(Drug  80% of
Time at Risk)
Univariate 0.10 (0.08–0.12) 0.03 (0.02–0.06)
Age and sex 0.24 (0.20–0.29) 0.08 (0.04–0.13)
Clinical risk factors* 0.29 (0.25–0.35) 0.09 (0.06–0.16)
Clinical risk factors*
and medication
All ages 0.32 (0.27–0.38) 0.11 (0.06–0.19)
<65 yrs 0.37 (0.24–0.55) 0.21 (0.08–0.56)
65–74 yrs 0.39 (0.30–0.51) 0.12 (0.06–0.28)
75 yrs 0.31 (0.23–0.41) 0.08 (0.03–0.22)
Propensity score matched 0.41 (0.33–0.51) 0.18 (0.10–0.31)
Values are hazard ratios (95% conﬁdence intervals). *Adjustment for factors marked by asterisk (*)
in Table 1 and for medication in Online Table 2.
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23800.38) (Table 2). Propensity score matching led to some
attenuation of the differences but did not eliminate the
survival beneﬁt associated with dronedarone use (HR: 0.41;
95% CI: 0.33 to 0.51).
Other antiarrhythmic drugs. Patients who used class I or
III antiarrhythmic drugs at baseline had better survival
than patients who did not (annual rates: 4.8% vs. 14.7%;
p < 0.0001). Among users of antiarrhythmic drugs, those
who used amiodarone had the highest annual mortality
(8.8%) (Fig. 3). Users of dronedarone and ﬂecainide had
the lowest mortality rate (1.3% per year). After adjustmentFigure 3
Unadjusted Mortality in Relation to
Antiarrhythmic Treatment at Baseline
Note abbreviation of scale. Cum ¼ cumulative.for cofactors, dronedarone use was still associated with
lower mortality than amiodarone (HR: 0.40; 95% CI: 0.31
to 0.51), whereas ﬂecainide use was not (HR: 0.67; 95% CI:
0.41 to 1.10) (Table 3). Sotalol-treated patients had the
same mortality risk as amiodarone-treated patients (HR:
1.02; 95% CI: 0.77 to 1.35).
Standardized mortality ratio. AF patients who had been
prescribed dronedarone had better survival than those in
the general population (SMR: 0.67; 95% CI: 0.55 to 0.78),
whereas patients who had not been prescribed drone-
darone had approximately twice the expected mortality
(SMR: 2.19; 95% CI: 2.17 to 2.21) (Table 4). For sub-
groups of patients with liver disease, renal failure, heart
failure, vascular disease, and diabetes mellitus, the SMR was
increased 3-5 fold in the non–dronedarone-exposed AF
population, whereas none of these factors were signiﬁcantly
associated with increased mortality in the dronedarone-
exposed group.
Heart failure patients. In the dronedarone group, 50 of
1,707 patients with a prior diagnosis of heart failure died
during follow-up, which represents an annualized mortality
rate of 2.9% (95% CI: 2.2% to 3.9%), which was barely
one-tenth of the mortality among heart failure patients in
the control group who did not receive dronedarone (23.9%;
95% CI: 23.6% to 24.2%; p < 0.0001). Of those who died,
39 (78%) had had access to less dronedarone than required
to last for one-half of the time at risk. Dronedarone-treated
heart failure patients were younger than the control sub-
jects (66.7  10.4 years vs. 79.6  10.3 years; p < 0.0001)
and healthier (e.g., CHA2DS2-VASc score [an AF risk
score on the basis age and history of congestive heart
failure, hypertension, diabetes mellitus, stroke/transient
ischemic attack/thromboembolism, and vascular disease]
3.6  1.6 vs. 4.9  1.7; p < 0.0001). The lower death risk
associated with dronedarone use among AF patients with a
prior hospital diagnosis of heart failure remained signiﬁ-
cant after adjustment for cofactors (HR: 0.40; 95% CI:
0.30 to 0.53).
Liver disease. During follow-up, 16 dronedarone-
exposed patients received a diagnosis of liver disease,
which represents an annual incidence of 0.22% (95%
CI: 0.12% to 0.35%) compared with 0.60% (95% CI:
0.57% to 0.64%) in the control population (p < 0.0001)
(Fig. 4). After propensity score matching, the annual
incidence of liver disease was no longer signiﬁcantly
higher than in the dronedarone group (0.22% vs. 0.37%;
p ¼ 0.104) (Fig. 5). Eleven of 16 dronedarone-exposed
patients who received a diagnosis of liver disease during
follow-up had not had access to enough dronedarone
needed to last even half the time at risk, and 4 others had
known liver problems when they started taking drone-
darone. Thus, only 3 patients received a new diagnosis of
liver disease while undergoing treatment, which repre-
sents an annualized rate of 0.04% (95% CI: 0.01% to
0.12%), far lower than in the nonexposed control group.
The risk of receiving a diagnosis of liver disease was lower
Table 3
Hazard Ratios for Death in Relation to Latest Antiarrhythmic Drug Purchase Up to
30 Days After Index Date
Mean Age
(yrs) n
Annual
Mortality (%) (CI)
HR Adjusted for
Age and Sex (CI)
HR With Multivariable
Adjustment (CI)
Class I
Disopyramide 72.9 744 4.6 (3.6–5.8) 0.48 (0.37–0.62) 0.62 (0.37–1.03)
Propafenone 65.1 57 3.4 (0.9–8.7) 0.66 (0.25–1.77) 0.74 (0.19–2.80)
Flecainide 63.5 2,331 1.3 (1.0–1.6) 0.30 (0.23–0.39) 0.67 (0.41–1.10)
Class III
Sotalol 73.5 5,722 7.8 (7.3–8.3) 0.70 (0.62–0.78) 1.02 (0.77–1.35)
Amiodarone 70.6 2,809 8.8 (8.0–9.7) Reference Reference
Dronedarone 65.5 4,698 1.3 (1.1–1.6) 0.26 (0.22–0.32) 0.40 (0.31–0.51)
CI ¼ 95% conﬁdence interval; HR ¼ hazard ratio.
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2381among dronedarone patients than among other AF
patients (HR: 0.57; 95% CI: 0.34 to 0.92).
Discussion
Patients prescribed dronedarone had a very favorable prog-
nosis. The age- and sex-adjusted overall mortality was even
lower than in the general population, in which relatively
few people have AF and even fewer take dronedarone. The
registers showed that many patients who were given dro-
nedarone had previously been diagnosed with heart failure,
which now is considered to be an absolute contraindication
to treatment; however, the study shows that these patients
fared much better than nonexposed heart failure patients.
Patients taking dronedarone had fewer liver problems than
patients who were not taking the drug.
High mortality in the control group. The ﬁnding of a
mortality rate among dronedarone patients that was less than
one-tenth that of other AF patients (1.3% vs. 14.0%) was in
part caused by a high death rate in the control group, more
than twice as high (SMR: 2.2) as in the general population.
Most other studies have shown an approximately 1.5-fold
increase in mortality for AF patients (17–20).Table 4 Standardized Mortality Ratios
Dronedarone
n SMR 95%
Men 2,857 0.70 0.54 to
Women 1,999 0.62 0.45 to
Age, yrs
<65 2,040 0.92 0.55 to
65–74 1,982 0.75 0.54 to
75 834 0.54 0.39 to
Heart failure 813 1.27 0.92 to
Vascular disease 687 1.15 0.81 to
Thromboembolism 584 0.73 0.42 to
Hypertension 3,189 0.76 0.62 to
Diabetes mellitus 549 1.09 0.66 to
Liver disease 38 2.17 0.29 t
Renal failure 97 1.73 0.71 to
All patients 4,856 0.67 0.55 to
CI ¼ conﬁdence interval; SMR ¼ standardized mortality ratio.Patient selection. Patients taking dronedarone were
younger and had less comorbidity than patients not taking
dronedarone, but even after adjustment for no fewer than
39 cofactors found in the registers, dronedarone use was still
associated with a large survival beneﬁt. Obviously, there are
other cofactors that affect prognosis that registry data do not
address.
Dronedarone is intended for patients with symptomatic,
nonpermanent AF. This targets dronedarone to patients
with a relatively active lifestyle, which is associated with a
better prognosis. The stratiﬁcation of patients according to
their likelihood of receiving dronedarone (propensity score
matching) did compensate for some of that hidden con-
founding but could not eliminate it.
Relation to other antiarrhythmic drugs. Prescription data
from registers are not suitable for head-to-head comparisons
between antiarrhythmic drugs, because patients have not
been randomized and data about drug exposure are incom-
plete. Interpretation of Table 3 must therefore be made with
caution. Randomized trials have not shown that antiar-
rhythmic drugs used for AF offer any survival beneﬁts
(2,21). The ﬁnding of reduced mortality among users of
antiarrhythmic drugs in the present study is a reﬂection ofNo Dronedarone
CI n SMR 95% CI
0.85 94,567 2.10 2.07 to 2.13
0.80 75,572 2.30 2.27 to 2.33
1.29 27.523 4.03 3.81 to 4.25
0.95 41,398 2.94 2.86 to 3.03
0.68 101,218 2.09 2.06 to 2.11
1.62 55,296 2.84 2.80 to 2.88
1.49 28,027 2.71 2.67 to 2.76
1.03 39,985 2.55 2.51 to 2.60
0.91 116,447 2.16 2.13 to 2.18
1.51 33,124 2.90 2.84 to 2.96
o 4.62 2,459 5.00 4.65 to 5.35
2.75 11,224 4.36 4.24 to 4.48
0.78 170,139 2.19 2.17 to 2.21
Figure 5
Unadjusted Incidence of Liver Disease After Pairwise
Matching for Propensity to Receive Dronedarone
Comparison of 4,856 patients with atrial ﬁbrillation exposed to dronedarone
and 4,856 AF patients not exposed to dronedarone. Note abbreviation of scale.
Cum ¼ cumulative.
Figure 4
Unadjusted Incidence of Liver Disease in Patients
Exposed to Dronedarone
Unadjusted incidence of liver disease in 4,856 patients with atrial ﬁbrillation
exposed to dronedarone compared with 170,139 patients with atrial ﬁbrillation not
exposed to dronedarone. Note abbreviation of scale. Cum ¼ cumulative.
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with antiarrhythmic drugs.
This is certainly true for ﬂecainide initiation in Sweden,
where most patients are subjected to bicycle ergometer tests,
echocardiography, and electrocardiographic monitoring
during the ﬁrst days of therapy to ensure there is no structural
heart disease that could lead to an increased risk of proar-
rhythmia. Initiation of dronedarone is not associated with
the same rigorous testing procedures. Flecainide and dro-
nedarone share the same low mortality rate in crude numbers.
This is most likely a reﬂection of more careful selection of
low-risk patients for ﬂecainide than for dronedarone. After
adjustment for cofactors, dronedarone but not ﬂecainide
was associated with signiﬁcantly lower mortality than amio-
darone, despite less extensive patient-selection procedures.
In Sweden, amiodarone is used primarily as the last resort
by patients for whom other drug therapy has been tried
without success, that is, patients who have progressed further
in their arrhythmic disease and thus have poorer prognosis.
Higher mortality among amiodarone users than among users
of ﬁrst-line drugs is therefore natural.
Sotalol has long been, and still is, the most commonly
used antiarrhythmic drug for AF patients in Sweden after
beta-blockers. One would expect that a drug that is used as
ﬁrst-line therapy would be prescribed for patients at lower
risk than a drug used after everything else has been tried.
However, the annual mortality rate of 7.8% placed sotalol
at the same level as amiodarone, which could indicate thatsotalol use could be harmful, as indicated by a recent
meta-analysis of randomized, placebo-controlled trials
published by the Cochrane collaboration (2).
Heart failure. Heart failure patients who were given dro-
nedarone had much lower mortality than heart failure pa-
tients who were not. This is contrary to the ﬁndings in
ANDROMEDA, in which patients randomized to drone-
darone had increased mortality. However, the patients in
the present study who had been categorized as having
heart failure were probably very unlike the patients in
ANDROMEDA, in which the inclusion criteria were that
there should have been at least 1 episode of shortness of
breath on minimal exertion or at rest (New York Heart
Association functional class III or IV) or paroxysmal
nocturnal dyspnea within the month before admission (8).
In keeping with the general picture that patients given
dronedarone in Sweden are handpicked, low-risk patients, it
is reasonable to believe that patients with heart failure who
were given dronedarone had a less severe form of heart
failure than heart failure patients in the control group. In
ATHENA, which included patients with milder degrees of
congestive heart failure, subgroup analyses demonstrated
beneﬁcial effects, in agreement with the overall study results
also seen in these patients (7).
Liver toxicity. Liver disease was less common among pa-
tients exposed to dronedarone than among those not
exposed to dronedarone. No liver diagnosis of any kind
appeared as a cause of death or a contributing cause of
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2383death for any patient who had ever been given dronedarone.
This does not rule out the possibility that some patients
may have had transient elevations of liver enzymes that
caused cessation of treatment without resulting in a diag-
nostic code, nor does it exclude the possibility that a very
small number of patients may have idiosyncratic reactions
that could not be detected in a study of this size. Notably,
some 150,000 patients had been prescribed dronedarone in
the United States before 2 cases of rapidly progressing liver
failure occurred that prompted the FDA and EMA to issue
their warnings about possible liver toxicity.
Exposure to dronedarone. Many patients prescribed dro-
nedarone stopped taking it after a while. The dispensed
quantities simply did not match the time at risk of these
patients. When dronedarone ﬁrst became available, there
were many patients who had tried several antiarrhythmic
agents without success and switched to dronedarone as a
last resort when it became available. These patients may
have failed to improve with dronedarone too and therefore
stopped taking it. In support of this view, it is noted that
60% of the patients who were prescribed dronedarone in
2010 had tried 1 or more class I or III antiarrhythmic agents
before they began taking dronedarone compared with 43%
in 2012.
Having access to a drug is not the same as taking it.
Patients who did not return for more dronedarone may have
stopped taking it before they ran out of supply. An analysis
of patients according to the intention-to-treat principle
means that some patients will be analyzed as taking drone-
darone even though they did not. This dilutes the data about
any harmful effects of dronedarone and makes it more
difﬁcult to detect such harmful effects. As a safeguard
against this, data were also analyzed according to the on-
treatment principle, whereby only patients with access to
enough dronedarone to last at least 80% of the time at risk
were counted as dronedarone patients. The results of this
analysis, however, were even more in favor of an advantage
of dronedarone use, because those who discontinued treat-
ment had higher mortality than those who continued
treatment (Table 2). Within the group of patients who had
been selected for dronedarone treatment and thus were less
susceptible to confounding by indication, a higher degree of
exposure to dronedarone was associated with better, not
worse, outcome. A possible reason for this could be that
patients who were later to die experienced treatment failure
with dronedarone more often than others or were therefore
taken off treatment more often.
Study limitations. Some of the limitations with the study
methodology have already been pointed out: confounding by
indication, lack of information about lifestyle factors, lack of
information about the degree of disease, and uncertainty
about the actual drug exposure. The positive predictive value
of the Patient Register is relatively good (13), but little is
known about the negative predictive value for most di-
agnoses, because this requires knowledge about true preva-
lences of diseases in the population, including subjectswho have not yet received a diagnosis. The number of sec-
ondary diagnoses used is relevant to the possibility of
detecting comorbidity from the register. The poorer the
health of a patient and the more competing diagnoses there
are, the less likely it is that codes will be given for diseases
that are not the primary cause for the contact or that
generally are considered as less acute and severe. A patient
who has a hospital contact for chest pain and heart failure,
for instance, but also has hypertension is likely to be listed
without a diagnosis of hypertension if only 1 or 2 diagnoses
are given.
Underdiagnosis is probably less common with diagnoses
that relate to discrete events, for instance, stroke or myo-
cardial infarction, than for diagnoses that relate to ongoing
conditions such as hypertension or obesity. Underestimation
of comorbidity is therefore far more likely than over-
estimation. Thus, confounding by indication will tend to
exaggerate differences between patients taking and not
taking dronedarone, whereas overestimation of drug expo-
sure and underestimation of comorbidity will tend to reduce
differences between exposed and nonexposed patients.
Finally, the results of the study may not be applicable in
countries where the prescription patterns for dronedarone
differ substantially from the conditions in Sweden.
Conclusions
Dronedarone, as prescribed to AF patients in Sweden, has
not exposed patients to increased risks of death or liver
disease.
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